Lundbeck
Lundbeck is a global pharmaceutical company specialized in brain diseases.
Launch date
Employees
Market cap
€5.9b
Enterprise valuation
€5.3b (Public information from Sep 2024)
Share price
DKK39.05 LUN.CO
Copenhagen Capital Region of Denmark (HQ)
Corporate Venture Fund: Lundbeckfonden Ventures
Financials
Estimates*
DKK | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 17.7b | 16.3b | 18.2b | 19.9b | 21.8b | 22.9b | 24.1b |
% growth | 4 % | (8 %) | 12 % | 9 % | 9 % | 5 % | 5 % |
EBITDA | 4.8b | 3.7b | 4.7b | 5.7b | 6.2b | 6.7b | 7.2b |
% EBITDA margin | 27 % | 23 % | 26 % | 28 % | 29 % | 29 % | 30 % |
Profit | 1.6b | 1.3b | 1.9b | 2.3b | 3.2b | 3.6b | 4.1b |
% profit margin | 9 % | 8 % | 11 % | 12 % | 15 % | 16 % | 17 % |
EV / revenue | - | - | 1.5x | 1.6x | 1.9x | 1.6x | 1.4x |
EV / EBITDA | - | - | 5.9x | 5.5x | 6.7x | 5.7x | 4.7x |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | Grant | ||
Total Funding | - |
Related Content
Recent News about Lundbeck
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Industry
By Round
Investments by Lundbeck
EditACQUISITION by Lundbeck May 2019
ACQUISITION by Allergan Jul 2015
ACQUISITION by Lundbeck Mar 2009
ACQUISITION by Lundbeck Sep 2019
ACQUISITION by Lundbeck May 2014
exited
ACQUISITION by Lundbeck Mar 2018